OneMedForum Panelist Aftab Jamil of BDO: Crowdfunding in Life Sciences is Feasible
As part of our look into the impact of the JOBS Act on emerging growth companies, OneMedForum will feature a panel devoted to the subject of crowdfunding in life sciences and new investment strategies following the implementation of this groundbreaking legislation.
Read more »ReCor Medical: Renal Denervation, and a New Approach to Reducing High Blood Pressure
What if there was a way to substantially reduce high blood pressure for patients who have tried everything? Renal denervation is a hot topic, and ReCor Medical offers a unique ultrasound approach to enhance this exciting therapy…
Read more »Clinova: Consumer Healthcare and Medical Devices Represent Significant Global Market Opportunity
OneMedRadio spoke with Clinova, a British pharmaceutical company focused on developing, manufacturing and marketing consumer healthcare products and medical device, has a rare global presence in multiple emerging markets, while also securing a significant market presence in Europe.
Read more »ExThera Medical: Will Its Seraph™ Device Eliminate Bacteremia and Prevent Sepsis at Point-of-Care?
The first start-up by Bob Ward—The Polymer Technology Group (PTG)—earned a 555X return for investors upon its sale in 2008 to DSM, the global life sciences and materials company. Now, Bob Ward’s swinging away at another potential homerun: ExThera Medical, a Berkeley, California-based company, with its scientific origins at the Karolinska Institute in Stockholm, Sweden.
Read more »What If There Was a Way to treat Heart Failure (HF) Patients without Opening Their Chest? There Is, and BioVentrix Is Making It Possible
In the US and EU, HF is one of the most frequent diagnoses, and accounts for 7.5 million hospital days per year. Three to five percent of patients die despite hospitalization, half go home unimproved, 25% are readmitted within 30 days, and 30% die in six months.
Read more »DBV Technologies’ VIASKIN®: Potential Revolution in Treating Allergy, Offering Up Hope to the Most Severe and Most Vulnerable Patients
DBV Technologies, whose shares are traded on segment C of Euronext Paris (Ticker: DBV), believes that its VIASKIN® platform is a game-changer, notably for children and adults who suffer from potentially lethal food allergies.
Read more »What If We Could Detect Alzheimer’s Disease with a Simple and Reliable Eye Test? Cognoptix Says There Is a Way…
Acton, Mass.-based Cognoptix (formerly Neuroptix) has developed an entirely novel, early-stage diagnostic for Alzheimer’s disease (AD) to allow treatment before significant neuronal loss and irreversible brain damage occurs.
Read more »Investing in Swiss Life Sciences
OneMedResearch produces white papers exploring investment strategies abroad. This white paper, entitled Investing in Swiss Life Sciences, explores the reasons […]
Read more »Investor Guide to Diagnostics
The research division of OneMedPlace has produced a quarterly Investor Guide to Diagnostics. This guide features: Our editorial series on […]
Read more »Investor Guide to Regenerative Medicine
The research division of OneMedPlace has produced a quarterly Investor Guide to Regenerative Medicine. This guide features: Our editorial series […]
Read more »